Jacqueline Diaz
Family Medicine · Sunny Isles Beach, FLNPI 1992991277
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. GSK accounts for 78.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $444 and has fallen 95.4% since, to $20 in 2025.
Across 7 payments — averaging $84.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$468
- Supernus Pharmaceuticals, Inc.$105
- Novo Nordisk$20
Across 217 payments — averaging $14,082 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Organon$1.7M
- Mylan Inc.$470K
- Chiesi USA, Inc.$419K
- Supernus Pharmaceuticals, Inc.$217K
- GSK$130K
- Biohaven Pharmaceutical Holding Company Ltd.$64K
- plus $84K from 2 others
What the payments were for
- Food & beverage$593100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 5 | $468 |
| Supernus Pharmaceuticals, Inc. | 1 | $105 |
| Novo Nordisk | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$593 in reported general payments places this provider in the 55th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $14,216 |
| JanuviaSitagliptin Phosphate | 11 | $7,148 |
| Atorvastatin Calcium | 57 | $373 |
| Losartan Potassium | 36 | $307 |
| Levothyroxine Sodium | 34 | $299 |
| Metoprolol Succinate | 22 | $295 |
| Tamsulosin Hcl | 24 | $195 |
| Irbesartan | 11 | $191 |
| FenofibrateFenofibrate Nanocrystallized | 12 | $181 |
| Escitalopram Oxalate | 13 | $159 |
| Rosuvastatin Calcium | 23 | $149 |
| Pantoprazole Sodium | 17 | $136 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 17 | $130 |
| Gabapentin | 12 | $121 |
| Lisinopril | 20 | $119 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Sunny Isles Beach
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.